Document Detail

Directly acting antivirals against hepatitis C virus.
MedLine Citation:
PMID:  21652618     Owner:  NLM     Status:  Publisher    
The approval of directly acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection will represent a major breakthrough for the 180 million persons infected worldwide. Paradoxically, hepatitis C is the only human chronic viral disease that can be cured, as all other pathogenic viruses infecting humans either display self-limited courses or establish non-eradicable persistent infections. Until now, treatment of chronic hepatitis C consisted of the combination of peginterferon-α plus ribavirin, which provided limited rates of cure and was associated with frequent side effects. Several DAA have been identified that inhibit the NS3 protease, the NS5B polymerase or the NS5A replication complex, and have entered the final steps of clinical development. These molecules, coupled with significant progress made in the recognition of more potent and safe interferon forms (e.g. interferon-λ) and host protein targets (e.g. alisporivir), are opening a new era in hepatitis C therapeutics. The expectations are so great that, to some extent, it is reminiscent of what happened in 1996 in the HIV field when the introduction of the first protease inhibitors as part of triple combinations revolutionized antiretroviral therapy. To maximize treatment success and reduce the likelihood of drug resistance selection, a proper individualization of hepatitis C therapy will be required, choosing the most convenient drugs and strategies according to distinct viral and host profiles. The complexity of HCV therapeutics has reached a point that presumably will lead to the birth of a new specialist, the HCV doctor.
Vincent Soriano; Eugenia Vispo; Eva Poveda; Pablo Labarga; Luz Martin-Carbonero; Jose Vicente Fernandez-Montero; Pablo Barreiro
Related Documents :
15214788 - Uncharged azt and d4t derivatives of phosphonoformic and phosphonoacetic acids as anti-...
8585738 - Efficacy of constant infusion of a-77003, an inhibitor of the human immunodeficiency vi...
21799568 - Pre-exposure prophylaxis of hiv.
22236118 - Recent progress in small molecule ccr5 antagonists as potential hiv-1 entry inhibitors.
23705668 - Assessment of knowledge, attitude and practice towards post exposure prophylaxis for hi...
18307778 - Use of who clinical stage for assessing patient eligibility to antiretroviral therapy i...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-6-7
Journal Detail:
Title:  The Journal of antimicrobial chemotherapy     Volume:  -     ISSN:  1460-2091     ISO Abbreviation:  -     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-6-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513617     Medline TA:  J Antimicrob Chemother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Open lung approach vs acute respiratory distress syndrome network ventilation in experimental acute ...
Next Document:  96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus wit...